FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Anxiety patents



      
           
This page is updated frequently with new Anxiety-related patent applications. Subscribe to the Anxiety RSS feed to automatically get the update: related Anxiety RSS feeds. RSS updates for this page: Anxiety RSS RSS


Date/App# patent app List of recent Anxiety-related patents
05/21/15
20150141669
 Prodrug of fluorine-containing amino acid patent thumbnailProdrug of fluorine-containing amino acid
Provided are a fluorine-containing amino acid prodrug represented by general formula (i) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, alzheimer's disease, huntington's chorea, parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases..
Taisho Pharmaceutical Co., Ltd.
05/21/15
20150141500
 Compositions and methods for the treatment of neurological diseases patent thumbnailCompositions and methods for the treatment of neurological diseases
The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
05/14/15
20150133499
 Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound patent thumbnailPharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-htp) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cns disorders, including depressive disorders, bipolar disorders, anxiety disorders, obesity and pain..
05/14/15
20150132282
 Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin patent thumbnailTreatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating ptsd.
04/30/15
20150119453
 Compositions and methods for the treatment of depression patent thumbnailCompositions and methods for the treatment of depression
The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
04/23/15
20150111876
 Sulfur-containing bicyclic compound patent thumbnailSulfur-containing bicyclic compound
A sulfur-containing bicyclic compound having a pam action of gabab, and it use for preventing and/or treating schizophrenia, cias, cognitive impairment, fragile x syndrome, autism spectrum disorder, spasticity, anxiety disorder, substance addiction, pain, fibromyalgia, or charcot-marie-tooth disease. A pharmaceutical composition for preventing and/or treating schizophrenia, cognitive impairment associated with schizophrenia (cias), cognitive impairment, fragile x syndrome, autism spectrum disorder, spasticity, anxiety disorder, substance addiction, pain, fibromyalgia, charcot-marie-tooth disease, or the like, which has a positive allosteric modulator (pam action) of gabab..
Astellas Pharma Inc.
04/09/15
20150099663
 Biomarkers patent thumbnailBiomarkers
The invention relates to biomarkers and a method of diagnosing or monitoring depression, anxiety disorder or other psychotic disorder.. .
Stichting Vu-vumc
03/26/15
20150086533
 Botulinum toxin and the treatment of primary disorders of mood and affect patent thumbnailBotulinum toxin and the treatment of primary disorders of mood and affect
A method of treating anxiety disorder comprising the steps of: identifying a subject with one or more symptoms of an anxiety disorder; a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of anxiety disorder.. .
Botulinum Toxin Research Associates, Inc.
03/19/15
20150080415
 Therapeutic agent for anxiety disorders patent thumbnailTherapeutic agent for anxiety disorders
Provided are an agent for the treatment and/or prophylaxis of an anxiety disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (i) wherein r1 represents aryl or the like, and r2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.. .
Kyowa Hakko Kirin Co., Ltd.
03/19/15
20150080411
 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride patent thumbnailPolymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
Merck Patentgesellschaft
03/19/15
20150080350

Bumetanide analogs, compositions and methods of use


The present invention provides bumetanide, analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, analogs and methods for their use.
Neuropro Therapeutics, Inc.
03/05/15
20150065577

Method of treating binge eating disorder


The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in adhd and add patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in adhd and add patients.
Lcs Group, Llc
02/12/15
20150045551

Fused azole derivative


The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia. Specifically, the invention provides fused azole derivatives represented by general formula (i) or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin 1b receptor:.
Taisho Pharmaceutical Co., Ltd
01/29/15
20150030602

Antibodies for the treatment and diagnosis of affective and anxiety disorders


A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with egf-like and two follistatin-like domains 2 (tmefe2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and kits comprising such antibody and derivatives thereof are described..
Phenoquest Ag
01/15/15
20150018365

Method of treatment of anxiety disorder comorbid with depression disorder


Or suitable pharmaceutical salts, hydrates or anhydrates thereof.. .
12/25/14
20140377363

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment


This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of compound i or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which compound i is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine..
H. Lundbeck A/s
11/27/14
20140350254

Heterocyclic compounds for the treatment of neurological and psychological disorders


Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
11/20/14
20140342021

Magnesium compositions and uses thereof for neurological disorders


A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
11/06/14
20140330089

Physiological feature extraction and fusion to assist in the diagnosis of post-traumatic stress disorder


Post-traumatic stress disorder (ptsd), and other anxiety disorders, are diagnosed via clinical interviews in which subjective self-reports of traumatic events and associated experiences are discussed with a mental health professional. The system and methods described herein classify and diagnose patients as suffering from anxiety disorders by measuring objective physiological measures, such as inter-heartbeat interval and skin conductance.
10/30/14
20140322369

Ellagitannins rich extracts composition


The present invention relates to a composition consisting of ellagitannins rich extracts originated from plant extracts of the fagaceae family, for use in a method for preventing or treating sleep and anxiety disorders, fatigue as well as for improving mood, reducing tension and raising energy in a subject.. .
10/23/14
20140315910

Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders


One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone.
10/23/14
20140315821

Treatments involving eslicarbazepine acetate or eslicarbazepine


The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.. .
10/02/14
20140296339

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity


Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
09/18/14
20140275115

Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride


The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
09/04/14
20140249173

Glutamate agents in the treatment of mental disorders


Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof.
09/04/14
20140249090

Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders


The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide s receptor (npsr), of the receptor tgr23 and/or of vasopressin receptor-related receptor 1 (vrr1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition.
08/28/14
20140243363

Methods and compositions for treating anxiety disorders or symptoms thereof


The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one receptor switcher and at least one endorphin enhancer.
08/14/14
20140228565

Thienopyrimidinone derivatives as mglur1 antagonists


Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as parkinson's disease and alzheimer's disease.
08/14/14
20140228377

Methylpiperidine derivative


A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (ox) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.. .
08/07/14
20140221395

Deuterium-enriched alkyl sulfonamides and uses thereof


The present invention is concerned with deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of anxiety disorders including, general anxiety disorder (gad), panic disorder (pd), post-traumatic stress disorder (ptsd), social phobia (sp), health anxiety (hypochondriasis), depression, major depressive disorders, unipolar depression, bipolar i depression disorder, bipolar ii depression disorder, treatment-resistant depression, single episodic and recurrent major depressive disorders, depression in the medically ill, attention deficit hyperactivity disorder (adhd), attention deficit disorder (add), obsessive-compulsive disorder (ocd), obsessive-compulsive personality disorder (ocpd), autism spectrum disorder (asd), schizophrenia, psychosis, epilepsy, seizures, hot flashes due to menopause, age-related macular degeneration (amd), premature ejaculation, male erectile dysfunction, sexual dysfunction, obesity, eating disorders, bulimia nervosa, anorexia nervosa, angina, migraine, pain, nociception, sleep disorders, insomnia, fibromyalgia, alcohol withdrawal, autism, rett's syndrome, cyclothymic disorder, neural injury, neurodegenerative diseases, parkinson's disease, parkinson's disease psychosis, huntington disease, alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, alzheimer's disease, schizophrenia, psychosis, depression, pain or discomfort associated with surgery and pain or discomfort associated with medical illness.. .
07/31/14
20140213961

Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion


A system and method for introducing one or more stimulating drugs and/or applying electrical stimulation to the brain to treat mood and/or anxiety disorders uses an implantable system control unit (scu), specifically an implantable signal/pulse generator (ipg) or microstimulator with one or more electrodes in the case of electrical stimulation, and an implantable pump with one or more catheters in the case of drug infusion. In cases requiring both electrical and drug stimulation, one or more scus are used.
07/31/14
20140213842

Methods and devices for treating primary headache


Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
07/24/14
20140206876

2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists


Provided is a 2-(substituted ethynyl)quinoline derivative having an mglur5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mglur5 receptor-mediated diseases such as alzheimer's disease, senile dementia, parkinson's disease, l-dopa-induced dyskinesia, huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile x syndrome, autism, migraine and gastroesophageal reflux disease (gerd)..
07/10/14
20140194525

Exo-s-mecamylamine formulation and use in treatment


A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg.
06/12/14
20140163240

Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane


The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence..
06/12/14
20140163043

Phenyl-piperazine derivatives as serotonin reuptake inhibitors


Wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder..
06/05/14
20140155952

Method of treating depression, mood disorders and anxiety disorders using neuromodulation


The present application involves a method and a system for using electrical stimulation and/or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and/or catheter that is in communication with a predetermined site which is coupled to a signal generator and/or infusion pump that release either an electrical signal and/or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and/or anxiety..
06/05/14
20140155677

Treatment of anxiety disorders by external application of ionizing radiation


Medical systems, devices, and methods provide improved radiosurgical techniques for treatment of anxiety disorders (such as post-traumatic stress disorder (ptsd), generalized anxiety disorder (gad), panic disorder, social phobia, specific phobia, and the like). Radiation can be directed from a radiation source outside the patient toward a target tissue deep within the patient's brain using a stereotactic radiosurgical platform, typically without having to impose the surgical trauma associated with accessing deep brain tissues.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Anxiety for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anxiety with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













1.1336

3792

459298 - 0 - 71